Klinische Studie

A multi-centre, non-interventional study of RElugolix as aNdrogen-deprivAtion therapy In patientS with advanced hormone-Sensitive prostate cANCEr(RENAISSANCE)A multi-centre, non-interventional study of RElugolix as aNdrogen-deprivAtion therapy In patientS with advanced hormone-Sensitive prostate cANCEr (RENAISSANCE)
Krankheitsentität(en) Prostata
StudientypBeobachtungsstudie
Wesentliche Einschlusskriterien1. Patient who had voluntarily signed and dated the informed consent form. 2. Patients who had histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate described in the patient’s file. 3. Patients deemed eligible for androgen-deprivation therapy with relugolix prescribed as part of standard clinical practice. 4. Patient who has agreed with the investigator the initiation of relugolix, per the investigator's decision, prior to enrollment into the study. 5. Intended duration of androgen-deprivation therapy of at least twelve months.
Wesentliche Ausschlusskriterien1. History of surgical castration. 2. Intended duration of androgen-deprivation therapy of less than 12 months. 3. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the product information. 4. Patient who has already received or is currently receiving relugolix. 5. Participant who is not treated in line with current Summary of Product Characteristics for relugolix.
Statusrekrutierend
Ansprechpartner & KontaktCaritas-Krankenhaus St. Josef RegensburgUrologieStudienzentrale0941 7823506uro-studienzentrum(at)csj.de
zurück